These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 38238757)
1. Testing the test strips: laboratory performance of fentanyl test strips. Halifax JC; Lim L; Ciccarone D; Lynch KL Harm Reduct J; 2024 Jan; 21(1):14. PubMed ID: 38238757 [TBL] [Abstract][Full Text] [Related]
2. High concentrations of illicit stimulants and cutting agents cause false positives on fentanyl test strips. Lockwood TE; Vervoordt A; Lieberman M Harm Reduct J; 2021 Mar; 18(1):30. PubMed ID: 33750405 [TBL] [Abstract][Full Text] [Related]
3. Assessment of two brands of fentanyl test strips with 251 synthetic opioids reveals "blind spots" in detection capabilities. Hayes KL; Lieberman M Harm Reduct J; 2023 Dec; 20(1):175. PubMed ID: 38057832 [TBL] [Abstract][Full Text] [Related]
4. Validation of a lateral flow chromatographic immunoassay for the detection of fentanyl in drug samples. Park JN; Sherman SG; Sigmund V; Breaud A; Martin K; Clarke WA Drug Alcohol Depend; 2022 Nov; 240():109610. PubMed ID: 36115223 [TBL] [Abstract][Full Text] [Related]
5. An urgent need for community lot testing of lateral flow fentanyl test strips marketed for harm reduction in Northern America. Lieberman M; Badea A; Desnoyers C; Hayes K; Park JN Harm Reduct J; 2024 Jun; 21(1):115. PubMed ID: 38877522 [TBL] [Abstract][Full Text] [Related]
6. Fentanyl test strips as an opioid overdose prevention strategy: Findings from a syringe services program in the Southeastern United States. Peiper NC; Clarke SD; Vincent LB; Ciccarone D; Kral AH; Zibbell JE Int J Drug Policy; 2019 Jan; 63():122-128. PubMed ID: 30292493 [TBL] [Abstract][Full Text] [Related]
7. Evaluating the sensitivity, stability, and cross-reactivity of commercial fentanyl immunoassay test strips. Rodriguez-Cruz SE J Forensic Sci; 2023 Sep; 68(5):1555-1569. PubMed ID: 37420315 [TBL] [Abstract][Full Text] [Related]
8. Differences in drug use behaviors that impact overdose risk among individuals who do and do not use fentanyl test strips for drug checking. Tilhou AS; Zaborek J; Baltes A; Salisbury-Afshar E; Malicki J; Brown R Harm Reduct J; 2023 Mar; 20(1):41. PubMed ID: 36978170 [TBL] [Abstract][Full Text] [Related]
9. High willingness to use rapid fentanyl test strips among young adults who use drugs. Krieger MS; Yedinak JL; Buxton JA; Lysyshyn M; Bernstein E; Rich JD; Green TC; Hadland SE; Marshall BDL Harm Reduct J; 2018 Feb; 15(1):7. PubMed ID: 29422052 [TBL] [Abstract][Full Text] [Related]
10. A pilot study assessing client understanding and use of fentanyl test strips for harm reduction. Barrolle AA; Gable KN; Dell N J Am Pharm Assoc (2003); 2023; 63(1):295-300. PubMed ID: 36280433 [TBL] [Abstract][Full Text] [Related]
11. Nitazene test strips: a laboratory evaluation. De Vrieze LM; Stove CP; Vandeputte MM Harm Reduct J; 2024 Aug; 21(1):159. PubMed ID: 39198843 [TBL] [Abstract][Full Text] [Related]
12. A lot testing protocol for quality assurance of fentanyl test strips for harm reduction applications. Fernando H; Amate A; Hayes KL; Whitehead HD; Desnoyers C; Uzobuife E; Denchfield MS; Whitelatch B; Lieberman M Harm Reduct J; 2024 Aug; 21(1):152. PubMed ID: 39169393 [TBL] [Abstract][Full Text] [Related]
13. Perspectives on rapid fentanyl test strips as a harm reduction practice among young adults who use drugs: a qualitative study. Goldman JE; Waye KM; Periera KA; Krieger MS; Yedinak JL; Marshall BDL Harm Reduct J; 2019 Jan; 16(1):3. PubMed ID: 30621699 [TBL] [Abstract][Full Text] [Related]
14. Fentanyl Test Strips for Harm Reduction: A Scoping Review. Kutscher E; Barber Grossi M; LaPolla F; Lee JD J Addict Med; 2024 Jul-Aug 01; 18(4):373-380. PubMed ID: 38829042 [TBL] [Abstract][Full Text] [Related]
15. Use of rapid fentanyl test strips among young adults who use drugs. Krieger MS; Goedel WC; Buxton JA; Lysyshyn M; Bernstein E; Sherman SG; Rich JD; Hadland SE; Green TC; Marshall BDL Int J Drug Policy; 2018 Nov; 61():52-58. PubMed ID: 30344005 [TBL] [Abstract][Full Text] [Related]
16. "You can't go wrong being safe": Motivations, patterns, and context surrounding use of fentanyl test strips for heroin and other drugs. Reed MK; Guth A; Salcedo VJ; Hom JK; Rising KL Int J Drug Policy; 2022 May; 103():103643. PubMed ID: 35255392 [TBL] [Abstract][Full Text] [Related]
17. Take-home drug checking as a novel harm reduction strategy in British Columbia, Canada. Klaire S; Janssen RM; Olson K; Bridgeman J; Korol EE; Chu T; Ghafari C; Sabeti S; Buxton JA; Lysyshyn M Int J Drug Policy; 2022 Aug; 106():103741. PubMed ID: 35671687 [TBL] [Abstract][Full Text] [Related]
18. Drug checking as a potential strategic overdose response in the fentanyl era. Laing MK; Tupper KW; Fairbairn N Int J Drug Policy; 2018 Dec; 62():59-66. PubMed ID: 30359874 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of fentanyl immunoassay test strips for rapid in-situ detection of fentanyl and fentanyl analogs in seized samples and alternative matrices. Norman C; Marland V; McKenzie C; Ménard H; Nic Daéid N Int J Drug Policy; 2023 Aug; 118():104102. PubMed ID: 37343365 [TBL] [Abstract][Full Text] [Related]
20. Monitoring for fentanyl within Australian supervised injecting facilities: Findings from feasibility testing of novel methods and collaborative workshops. Nielsen S; Barratt M; Hiley S; Bartlett M; Latimer J; Jauncey M; Roux C; Morelato M; Clark N; Kowalski M; Gilbert M; Francia L; Shipton A; Gerostamoulos D; Glowacki L; Lam T Int J Drug Policy; 2023 May; 115():104015. PubMed ID: 37043848 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]